patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
3-2-16, Pluristem's Radiation Antidote Bests Blockbuster Drug Neupogen
PLX-R18 Heals 100% of Population Exposed To Lethal Radiation through Nuclear Accident or Attack; Ready To Supply U.S. Government.
2-2-15, Significant New Finding From Its Phase I/II Muscle Injury Trial - Excellent Safety Profile for Cells at Twelve Months.
Data showed the magnitude of improvement in muscle force of 40 times larger in patients treated with PLX-PAD.
3-6-14, US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process.
Pluristem Fortifies Leadership Position in Cell Therapy Following Multiple Regulatory Approvals of Its New PLX Cell Mass Production Facility.
The PluriX™ Bioreactor
System is designed to creates an artificial physiological environment where cells (ASCs) can grow and reproduce outside of the human body. By mimicking the natural environment that exists within human bones, the system “tricks” stem cells into growing and reproducing in the same way they would in living organs. Because the size and scale of the PluriX™ Bioreactor is larger than that of human bone marrow, stem cell growth can be greatly expanded.
1-18-11, Pluristem on Track to Proceed to a Phase II/III Clinical Trial in Critical Limb Ischemia (CLI) Under a Joint FDA-EMA Protocol, and a Phase II Clinical Trial in Intermittent Claudication (IC)
Data from Clinical Trials Show Pluristem's Placenta-Derived Cell Therapy is Safe and Improves Quality of Life and Efficacy Measurements in Patients With Critical Limb Ischemia
“The results of these trials provide a strong indication of the potential success of commercializing PLX-PAD,” said Zami Aberman, President, Chairman and CEO of Pluristem
6-28-10, Pluristem is Advancing Toward Two Phase IIb Clinical Trials for Treatment of Critical Limb Ischemia and Moderate-Severe Claudication.
Company Awarded a $2.5 Million Grant from Israeli Government.
5-20-10, Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus of Presentations at Upcoming Investor and Medical Conferences
Chaya Mazouz, the company’s vice president of clinical and regulatory affairs, will present information about the regulatory study design considerations for PLX-PAD, the company’s lead cell therapy candidate for the treatment of critical limb ischemia (CLI), at 11 a.m. EDT on May 24 at the International Society for Cellular Therapy’s (ISCT) 16th Annual Meeting in Philadelphia
11-17-09, Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD.
Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured Efficacy Parameters.
9-10-09, Pluristem Begins Enrollment in U.S. in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease.
It has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD for the treatment of critical limb ischemia, of (PAD).
Click to see Dr. Prathers' PowerPointPresentation.
The title of the conference was “Stem Cell Therapy – The Future of Medicine” and was held on March 19, 2009 at the Marriot Del Mar Hotel in San Diego, California. Dr. Prather presented an overview of Pluristem and an update on the clinical development of the Company’s placental-derived (PLX) stem cells.
Pluristem Therapeutics Receives FDA Clearance to Begin “First-In-Human” Placenta-Derived Stem Cell Clinical Trial
Clearance of IND Filing Paves Way for US-based Trial That Will Enroll Patients with Critical Limb Ischemia Who Are Facing Amputation
PSTI - As of 02/22/09, 03:52:21 PM:
326 Insider Transactions